Celsion Corp. shares rose nearly 20% in premarket trade Thursday after the company said the Food and Drug Administration had cleared its ovarian cancer therapy for a phase 1/2 clinical trial. The company plans to begin enrolling patients in the phase 1 part of the trial in the first half of the year, and expects to have a quarter of the study enrolled by the end of 2018. GEN-1 is a DNA-based immunotherapy for the local treatment of ovarian cancer. Celsion shares have plummeted 28.4% over the last three months, compared with a 6.9% rise in the S&P 500 and a 10% rise in the Dow Jones Industrial Average .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News